Shepherd Ventures — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
DiaMedica Therapeutics develops therapies aimed at reducing ischemia in patients with serious vascular diseases, with an initial focus on preeclampsia, fetal growth restriction, and acute ischemic stroke.
BiotechDigital HealthMinneapolis, US
David J. Wambeke(Executive Officer)inLorianne Masuoka(Executive Officer)inRick Pauls(Executive Officer, Director)inScott Kellen(Executive Officer)inTodd Verdoorn(Executive Officer)inPaul Papi(Executive Officer)
Board seatRichard P. Kuntz· per SEC Form D · $37.5M raise · filed Jun 2023
Co-investorsCentreStone Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.